BullishMEDIUM severityHealthcare & Pharma96d ago

Nurix Therapeutics stock hits 52-week high at $26.40

Nurix Therapeutics stock hits 52-week high at $26.40 — $NRIX one-month chart
$NRIX daily closes over the past month · Wook of Wall Street artwork from market data

At a glance

WOOKAI ASSISTANTREADY
WOOK AIASK ANYTHING · NEVER ADVISES

Ask about NRIX. Get explanations, comparisons and calculations with the source lookups shown.

Risk check · nurix therapeuticsEvent risk Low

Nothing reported about nurix therapeutics across key-person, legal, regulatory, security, operational or financial-integrity risk in three weeks of coverage and 30 days of SEC filings.

From here · last month’s volatility 142% a year
Now $14.73Week $11.78–$17.68 (±20.0%)Month $8.68–$20.78 (±41.0%)
Ask Wook AI

Ranges are one standard deviation of volatility around the latest close — about 1 week in 3 moves further. Not a forecast or investment advice.

Wook analysis

What it means

Key points
  • What to watch: There is a hard number in this story ($26.40) — the interesting part is how it compares with the last few like it.
  • How the stock is trading: $NRIX -4.84% in the latest session.
  • Timing: It came out during market hours, so traders could react the same day, and the session move may reflect that.
Amount$26.40

Where the stock stands

Nurix Therapeutics ($NRIX) dropped 4.84% to $14.73 in the latest session. Over the past month it is down 40.9%. That leaves it 48% below its 52-week high of $28.23 and 19% above its low of $12.43. It has been a volatile year: the high was 2.3 times the low, so moves this size are not unusual for it.

What the filings say

In its latest report (10-Q, filed Oct 13, 2026), $NRIX earned $549.8M over the quarter to Aug 31, 2026 on revenue of $673.1M (+7342.9% QoQ). Operations brought in $447.1M of cash over the nine months to Aug 31, 2026; after capital spending, free cash flow was $442.8M. Total liabilities were $227.0M against $720.2M of cash on Aug 31, 2026. Its most recent filings before this story: 10-Q on Jul 9, 2026, 8-K on Jul 9, 2026, 8-K on Jun 11, 2026. Figures are as filed with the SEC; the $NRIX page has the full statements.

How much coverage it is getting

Nothing new on Nurix Therapeutics has come through Wook's feeds in the last 30 days, so this is still the most recent story on it.

The bigger picture

Healthcare stories turn on approvals, trial data and pricing: one FDA decision or trial readout can swing a single drugmaker hard, while drug-pricing policy moves the whole group at once. Wook's supply-chain scanner shows no unusual stress in Health Care today.

What to watch next

The company's own filings are the primary source. Its latest SEC reports, including any filing on a material event, are on the $NRIX page, and they say what management has disclosed without a reporter in between. Reading how two or three outlets frame the same story is the quickest way to separate the facts from the angle. Wook AI, at the top of the page, can work out how far $NRIX is from its high or compare this week's coverage with earlier weeks.

Discussion

No one has weighed in yet. Start the discussion on this story.

What happened after this published

Investing.com published this on August 12, 2026. $NRIX has moved -45.83% ($27.19 to $14.73). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.

Headline and link are attributed to Investing.com. Wook of Wall Street is an independent research tool and is not affiliated with Investing.com. Nothing here is financial advice or a recommendation — research and educational content only.

Choose what Wook may measure. Essential sign-in and security cookies stay on.

Read the privacy policy